色婷婷综合成人av_99久久精品国产毛片_成人一区二区在线_国产91丝袜在线播放_久久人人爽人人爽人人片av免费_欧美伊人

北愛爾蘭Fusion Antibodies 
Fusion, established in 2001 as a spin-out from Queen’s University Belfast, has won a host of awards for its leading-edge technology platform FET (Fusion Expression Technology). This enabling technology accelerates the validation of targets from DNA sequence through to recombinant protein expression. Fusion generates target specific antibodies from protein antigens with capability, through its antibody engineering know-how, to modify their characteristics to increase efficacy.

These technologies and associated microbiological techniques, in addition to supporting Fusion’s own therapeutic and diagnostic R&D, are offered as a service to pharmaceutical, biopharmaceutical and academic researchers, allowing them to achieve their goals faster and more cost effectively. Fusion has expertise in producing specific antibodies for therapeutic, diagnostic and theranostic applications.

Fusion Antibodies are world leaders in the bioinformatic design, rapid expression & purification of recombinant proteins via our award winning rapid high through-put platform. These high quality recombinant proteins form the basis of our monoclonal and recombinant antibody services, which we use to validate our R&D oncology drug discovery programme.
Fusion Antibodies provide customer focused recombinant protein engineering services to the bioscience industry.
Our leading-edge technology platform FET? (Fusion Expression Technology) accelerates the validation of targets from DNA sequence through to recombinant protein expression finally generating target specific antibodies.
Fusion also provides custom antibody engineering and a rapid monoclonal sequencing service which includes an option for 5’RACE amplification.